Pegylated interferon alfa-2a (pegIFNα-2a)

BIOLOGICAL3 trials

Sponsors

Bristol-Myers Squibb, Janssen-Cilag International NV

Conditions

Hepatitis CHepatitis C Virus (HCV)Hepatitis C, ChronicInfection

Phase 2

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

CompletedNCT01309932

Bristol-Myers SquibbHepatitis C

Start: 2011-03-31End: 2014-09-30Updated: 2015-10-09

Phase 3

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

CompletedNCT01616524

Bristol-Myers SquibbHepatitis C Virus (HCV)

Start: 2012-07-31End: 2014-09-30Updated: 2015-10-09

A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection

CompletedNCT01846832

Janssen-Cilag International NVHepatitis C, Chronic, Infection

Start: 2013-09-30End: 2015-08-31Updated: 2016-09-21

Related Papers

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response

PLoS ONE2017-01-058 citations

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)

PLoS ONE2016-07-184 citations